Melanoma News and Research

Latest Melanoma News and Research

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

ALDH enzyme marks melanoma stem cells

Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.

24 Aug 2012

Study shows how cancer survival rates developed in West Germany

Data from the 1970s and 1980s show that people affected by cancer survived significantly longer in West Germany than cancer patients behind the Iron Curtain.

24 Aug 2012

Article describes immune-related adverse events with newly approved melanoma drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

23 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.

18 Aug 2012

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.

16 Aug 2012

Inhibiting over-production of Panx1 protein can treat melanoma

New research from Western University, Canada, has identified a potential new target for the treatment of melanoma, the deadliest of all skin cancers. Silvia Penuela and Dale Laird discovered a new channel-forming protein called Pannexin (Panx1) that is expressed in normal levels on the surface of healthy skin cells.

16 Aug 2012

MedPage Today, CollabRx sign license agreement for Oncology Next

Tegal Corporation today announced that its recently acquired CollabRx, Inc., subsidiary signed an exclusive license agreement to provide a version of its proprietary Therapy Finder tool to MedPage Today, Everyday Health, Inc.'s rapidly growing online site that serves 96% of all oncologists and 1.6 million monthly online unique users.

9 Aug 2012

Chemotherapy is appropriate adjunct to surgery for oral melanoma in dogs

The addition of chemotherapeutic treatment with carboplatin for dogs with oral malignant melanomas that have undergone surgical excision may be a reasonable alternative to adjunctive radiotherapy, report researchers.

8 Aug 2012

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

Chemotherapy kills tumor cells, but it also wreaks havoc on the rest of the body. A team of researchers led by Igor Roninson of the South Carolina College of Pharmacy just reported the discovery of a new class of drugs that reduces the adverse effects of cellular damage from chemotherapy.

8 Aug 2012

UV dosimeter technology helps prevent over-exposure to the sun

A monitor developed at the University of Strathclyde in Glasgow, Scotland, to help prevent over-exposure to the sun is set to go on the market as part of a new spinout company.

7 Aug 2012

Depression in kidney cancer patients associated with survival and inflammatory gene regulation

Research from The University of Texas MD Anderson Cancer Center has found that symptoms of depression in patients with newly diagnosed metastatic kidney cancer are associated with survival and inflammatory gene regulation may explain this link.

3 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Photoacoustics limited in its ability to identify multiple types of cancer

One person dies every hour from melanoma skin cancer in the United States, according to the American Cancer Society. A technique, known as photoacoustics, can find some forms of melanoma even if only a few cancerous cells exist, but a recent study by MU researchers found that the technique was limited in its ability to identify other types of cancer.

31 Jul 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.

26 Jul 2012

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

26 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

Melanoma News and Research

Latest Melanoma News and Research

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

ALDH enzyme marks melanoma stem cells

Study shows how cancer survival rates developed in West Germany

Article describes immune-related adverse events with newly approved melanoma drug

Mayo Clinic receives approval for construction of new building on Phoenix campus

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Inhibiting over-production of Panx1 protein can treat melanoma

MedPage Today, CollabRx sign license agreement for Oncology Next

Chemotherapy is appropriate adjunct to surgery for oral melanoma in dogs

New class of drugs reduces adverse effects of cellular damage from cancer chemotherapy

UV dosimeter technology helps prevent over-exposure to the sun

Depression in kidney cancer patients associated with survival and inflammatory gene regulation

Australia's top medical researchers for 2012 announced

Photoacoustics limited in its ability to identify multiple types of cancer

Promising implications for improving cellular immunotherapy for treatment of cancer

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

MASL protein from plant's seeds may halt spread of melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in